A new FDA-approved drug offers new hope for patients with multidrug-resistant HIV-1 infection.
Editor's Choice FORM
FDA approved the first direct-to-consumer test for three specific BRCA1/BRCA2 breast cancer gene mutations.
During the worst flu season in years, FDA is warning consumers about fraudulent and counterfeit flu and antiviral products from online pharmacies.
The first radioactive drug to treat a certain type of cancer is among the top 3 new drug approvals for cancer. Here are the other top cancer drug approvals so far in 2018.
A pharmacist organization is among the supporters of a new Medicare Part D proposal, which calls for a 7-day supply limit on opioid prescriptions.
While hospitals continue to face IV saline shortages after two hurricanes significantly damaged infrastructure in Puerto Rico, the situation should improve early this year.
New blockbuster drugs to treat various conditions are expected to be among the top drugs to hit the marketplace in 2018. Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.
FDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).
FDA okays the first short-acting insulin approved as a “follow-on” product.
A new biosimilar to the cancer drug Herceptin, which raked in $2.5 billion in US sales last year, is expected to produce blockbuster sales in the US.